^
No biomarker
Oral Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Oral Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Oral Cancer
cisplatin + paclitaxel + 5-fluorouracil
Sensitive
:
A2
No biomarker
Oral Cancer
paclitaxel
Sensitive
:
A2
No biomarker
Oral Cancer
nivolumab
Sensitive
:
A2
No biomarker
Oral Cancer
methotrexate
Sensitive
:
A2
No biomarker
Oral Cancer
docetaxel
Sensitive
:
A2
No biomarker
Oral Cancer
cisplatin + docetaxel
Sensitive
:
A2
No biomarker
Oral Cancer
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Oral Cancer
cetuximab
Sensitive
:
A2
No biomarker
Oral Cancer
capecitabine
Sensitive
:
A2
No biomarker
Oral Cancer
afatinib
Sensitive
:
A2
No biomarker
Oral Cancer
5-fluorouracil
Sensitive
:
A2
No biomarker
Oral Cancer
cisplatin
Sensitive
:
A2
No biomarker
Oral Cancer
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A2
No biomarker
Oral Cancer
cisplatin + paclitaxel
Sensitive
:
A2
No biomarker
Oral Cancer
cisplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Oral Cancer
5-fluorouracil + hydroxyurea
Sensitive
:
A2
No biomarker
Oral Cancer
carboplatin + 5-fluorouracil
Sensitive
:
A2
GDF15 overexpression
Oral Cancer
TPF
Sensitive
:
C3
POU5F1 overexpression + NANOG overexpression
Oral Cancer
cisplatin
Resistant
:
C3
miR-1290-L
Oral Cancer
5-fluorouracil
Sensitive
:
C3
KRAS mutation
Oral Cancer
cetuximab
Resistant
:
C3
PD-L1 overexpression
Oral Cancer
nivolumab + MGCD516
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our